Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133 · MUIR-3 Phase 3Completed
- Lead sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrollment
- 1,456 (actual)
- Start date
- 21 May 2024
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 8 Sep 2026
- Last update posted
- 25 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Plozasiran Injection Drug
- Placebo Drug
Conditions and primary outcome
- Hypertriglyceridemia
Primary outcome
Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo (Baseline, Month 12)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06347133.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06347133 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.